Spasticity Management: Nonoperative and Operative

  • Heakyung KimEmail author
  • Eduardo Del Rosario
  • Richard Anderson
  • Nicole Bainton
  • Jared Levin
  • Angeline Bowman


Spasticity in patients with cerebral palsy is a common problem and leads to pain and development of orthopedic impairments as a patient ages. There are a multitude of options both surgical and nonsurgical that are currently utilized to help control spasticity in an attempt to prevent the known consequences on growth. This chapter overviews spasticity, how to assess it, and how to manage it through oral medications, local injections, and surgical interventions including intrathecal baclofen and selective dorsal rhizotomy.


Spasticity Botulinum toxin Intrathecal baclofen Selective dorsal rhizotomy 


  1. 1.
    Van Naarden BK, Doernberg N, Schieve L, et al. Birth prevalence of cerebral palsy: a population-based study. Pediatrics. 2016;137(1):e20152872.Google Scholar
  2. 2.
    Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartneberg Lecture. Neurology. 1980;30(12):1303–13.PubMedGoogle Scholar
  3. 3.
    Patrick E, Ada L. The Tardieu scale differentiates contracture from spasticity whereas the Ashworth scale is confounded by it. Clin Rehabil. 2006;20(2):173–82.PubMedGoogle Scholar
  4. 4.
    Knights S, Datoo N, Kawamura A, et al. Further evaluation of the scoring, reli- ability, and validity of the hypertonia assessment tool (HAT). J Child Neurol. 2014;29(4):500.PubMedGoogle Scholar
  5. 5.
    Meseguer-Henarejos AB, Sanchez-Meca J, Lopez-Pina JA, Carles-Hernandez R. Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis. Eur J Phys Rehabil Med. 2018;54(4):576–90.PubMedGoogle Scholar
  6. 6.
    Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6:23–35.Google Scholar
  7. 7.
    Fosang AL, Galea MP, Mccoy AT, Reddihough DS, Story I. Measures of muscle and joint performance in the lower limb of children with cerebral palsy. Dev Med Child Neurol. 2003;45(10):664–70.PubMedGoogle Scholar
  8. 8.
    Banky M, Clark R, Pua Y, Mentiplat B, Olver J, Williams G. Inter- and intra-rater variability of testing velocity when assessing lower limb spasticity. J Rehabil Med. 2019;51:54–60.PubMedGoogle Scholar
  9. 9.
    Nance PW, Young RR. Antispasticity medications. Phys Med Rehabil Clin N Am. 1999;10:337–55.PubMedGoogle Scholar
  10. 10.
    Young RR, Delaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med. 1981;304:96–9.PubMedGoogle Scholar
  11. 11.
    Young RR, Emre M, Nance PW, et al. Current issues in spasticity management. Neurologist. 1997;3:261–75.Google Scholar
  12. 12.
    Katz RT, Campagnolo DI. Pharmacologic management of spasticity. Phys Med Rehabil State Art Rev. 1994;8:473–80.Google Scholar
  13. 13.
    Mandac BR, Hurvitz EA, Nelson VS. Hyperthermia associated with baclofen withdrawal and increased spasticity. Arch Phys Med Rehabil. 1993;74:96–7.PubMedGoogle Scholar
  14. 14.
    He Y, Brunstrom-Hernandez JE, Thio LL, et al. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. J Pediatr. 2014;164:1181–8.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Alonso RJ, Mancall EL. The clinical management of spasticity. Semin Neurol. 1991;11:215–9.PubMedGoogle Scholar
  16. 16.
    Watanabe TK. Role of oral medications in spasticity management. Phys Med Rehabil. 2009;1:839–41.Google Scholar
  17. 17.
    Nance PW. Tizanidine: an alpha2-agonist imidazoline with anti-spasticity effects. Today’s Ther Trends. 1997;15:11–25.Google Scholar
  18. 18.
    PDR Tizanidine Dosage and Indications. Retrieved March 4, 2019.
  19. 19.
    Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs. 1986;32:130–68.PubMedGoogle Scholar
  20. 20.
    Young RR, Delaide PJ. Drug therapy: spasticity (first of two parts). N Engl J Med. 1981;304:28–33.PubMedGoogle Scholar
  21. 21.
    Taketomo CK, et al. Pediatric & neonatal dosage handbook a universal resource for clinicians: treating pediatric and neonatal patients; 2016–2017. 23rd ed. Hudson: Lexi-Comp; 2016.Google Scholar
  22. 22.
    Sieghart W. Pharmacology of benzodiazepine receptors: an update. J Psychiatry Neurosci. 1994;19:24–9.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol. 2001;16:31–6.PubMedGoogle Scholar
  24. 24.
    Verrotti A, Greco R, Spalice A, et al. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol. 2006;34:1–6.PubMedGoogle Scholar
  25. 25.
    Whelan MA, Frcpc FM. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;75(7):669.PubMedGoogle Scholar
  26. 26.
    Munchau A. Regular review: uses of botulinum toxin injection in medicine today. BMJ. 2000;320(7228):161–5.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Tilton AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol. 2003;18(1_suppl):S50–66.PubMedGoogle Scholar
  28. 28.
    Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131–8.PubMedGoogle Scholar
  29. 29.
    Riedel P, Marino MH. Pharmacologic treatment tools: systemic medications and toxins, opportunities, and pitfalls. Phys Med Rehabil Clin N Am. 2018;9(3):501–17.Google Scholar
  30. 30.
    de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–5.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Brin M, Aoki KR. Botulinum toxin type a: pharmacology. In: Mayer N, Simpson DM, editors. Spasticity—etiology, evaluation, management and the role of botulinium toxin. New York: WE MOVE; 2002. p. 110–24.Google Scholar
  32. 32.
    Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum a toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck. 1990;12(5):392–9.PubMedGoogle Scholar
  33. 33.
    Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum a toxin injections. Mov Disord. 1994;9(1):31–9.PubMedGoogle Scholar
  34. 34.
    Phadke C, Balasubramanian C, Holz A, Davidson C, Ismail F, Boulias C. Adverse clinical effects of botulinum toxin intramuscular injections for spasticity. Can J Neurol Sci. 2016;43(2):298–310.PubMedGoogle Scholar
  35. 35.
    Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin. 2009;25(7):1573–84.PubMedGoogle Scholar
  36. 36.
    Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil. 2004;83(suppl):S30–7.PubMedGoogle Scholar
  37. 37.
    D’Souza RS, Warner NS. Phenol nerve block. [Updated 2019 Feb 28]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2019. Available from:
  38. 38.
    Swerdlow M. Intrathecal neurolysis. Anaesthesia. 1978;33(8):733–40.PubMedGoogle Scholar
  39. 39.
    Zafonte RD, Munin MC. Phenol and alcohol blocks for the treatment of spasticity. Phys Med Rehabil Clin N Am. 2001;12:817–32.PubMedGoogle Scholar
  40. 40.
    Gormley ME Jr, Krach L, Piccini L. Spasticity management in the child with spasticity quadriplegia. Eur J Neurol. 2001;8(Suppl 5):127–35.PubMedGoogle Scholar
  41. 41.
    Morrison JE Jr, Matthews D, Washington R, Fennessey PV, Harrison LM. Phenol motor point blocks in children: plasma concentrations and cardiac dysrythmias. Anesthesiology. 1991;75:359–62.PubMedGoogle Scholar
  42. 42.
    Grigoriu A, Dinomais M, Rémy-Néris O, Brochard S. Impact of injection-guiding techniques on the effectiveness of botulinum toxin for the treatment of focal spasticity and dystonia: a systematic review. Arch Phys Med Rehabil. 2015;96(11):2067–78.PubMedGoogle Scholar
  43. 43.
    Santamato A, Micello MF, Panza F, Fortunato F, Baricich A, Cisari C, Ranieri M. Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. J Neurol Sci. 2014;347(1–2):39–43.PubMedGoogle Scholar
  44. 44.
    Irkoren S, Ozkan HS, Karaca H. A clinical comparison of EMLA cream and ethyl chloride spray application for pain relief of forehead botulinum toxin injection. Ann Plast Surg. 2015;75(3):272–4.PubMedGoogle Scholar
  45. 45.
    Çelik G, Özbek O, Yılmaz M, Duman I, Özbek S, Apiliogullari S. Vapocoolant spray vs lidocaine/prilocaine cream for reducing the pain of venipuncture in hemodialysis patients: a randomized, placebo-controlled, crossover study. Int J Med Sci. 2011;8(7):623–7.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Gupta A, Scott K, Dukewich M. Innovative technology using virtual reality in the treatment of pain: does it reduce pain via distraction, or is there more to it? Pain Med. 2018;19(1):151–9.PubMedGoogle Scholar
  47. 47.
    Aydin D, Sahiner NC. Effects of music therapy and distraction cards on pain relief during phlebotomy in children. Appl Nurs Res. 2017;33:164–8.PubMedGoogle Scholar
  48. 48.
    Alcaraz J, Oliver A, Sanchez JM. Platelet-rich plasma in a patient with cerebral palsy. Am J Case Rep. 2015;16:469–72.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Švehlík M, Steinwender G, Kraus T, Saraph V, Lehmann T, Linhart WE, Zwick EB. The influence of age at single-event multilevel surgery on outcome in children with cerebral palsy who walk with flexed knee gait. Dev Med Child Neurol. 2011;53(8):730–5.PubMedGoogle Scholar
  50. 50.
    Gooch JL, Patton CP. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil [Internet]. 2004;85(7):1121–4.Google Scholar
  51. 51.
    Ploypetch T, Kwon J-Y, Armstrong HF, Kim H. A retrospective review of unintended effects following single-event multi-level chemoneurolysis with botulinum toxin-a and phenol in children with cerebral palsy. PM&R [Internet]. 2015;7(10):1073–80.Google Scholar
  52. 52.
    Kim H, Lee Y, Weiner D, Kaye R, Cahill AM, Yudkoff M. Botulinum toxin type a injections to salivary glands: combination with single event multilevel chemoneurolysis in 2 children with severe spastic quadriplegic cerebral palsy. Arch Phys Med Rehabil. 2006;87(1):141–4.PubMedGoogle Scholar
  53. 53.
    Bar-On L, Molenaers G, Aertbeliën E, Van Campenhout A, Feys H, Nuttin B, Desloovere K. Spasticity and its contribution to hypertonia in cerebral palsy. BioMed Res Int. 2015;2015:317047. Scholar
  54. 54.
    Borowski A, Littleton A, Borkhuu B, Presedo A, Shah S, Dabney K, Lyons S, McMannus M, Miller F. Complications of intrathecal baclofen pump therapy in pediatric patients. J Pediatr Orthop. 2010;30(1):76–81.PubMedGoogle Scholar
  55. 55.
    Miller F. Cerebral palsy. New York: Springer Science Business Media; 2005.Google Scholar
  56. 56.
    Russman BS, Tilton A, Gormley ME. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve. 1997;20(S6):181–93.Google Scholar
  57. 57.
    Sala DA, Grant AD, Kummer FJ. Equinus deformity in cerebral palsy: recurrence after tendo achillis lengthening. Dev Med Child Neurol. 1997;39(1):45–8.PubMedGoogle Scholar
  58. 58.
    Sussman M, Aiona M. Treatment of spastic diplegia in patients with cerebral palsy. J Pediatr Orthop B. 2004;13(2):S12.Google Scholar
  59. 59.
    Stewart K, Harvey A, Johnston LM. A systematic review of scales to measure dystonia and choreoathetosis in children with dyskinetic cerebral palsy. Dev Med Child Neurol. 2017;59(8):786–95.PubMedGoogle Scholar
  60. 60.
    Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. Pediatrics. 2003;111(1):e89–97.PubMedGoogle Scholar
  61. 61.
    Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord. 2010;25:1538–49.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet. 1984;i:1078.Google Scholar
  63. 63.
    Albright A, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA. 1991;265:1418–22.PubMedGoogle Scholar
  64. 64.
    Sees JP, Miller F. Intrathecal medication administration in cerebral palsy. (2019) In: Miller F, Bachrach S, Lennon N, O’Neil M (eds) Cerebral palsy, Springer, Cham.Google Scholar
  65. 65.
    Albright AL, Gilmartin R, Swift D, et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg. 2003;98:291–5.PubMedGoogle Scholar
  66. 66.
    Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil. 1996;77:35–9.PubMedGoogle Scholar
  67. 67.
    Campbell WM, Ferrel A, McLaughlin JF. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol. 2002;44:660–5.PubMedGoogle Scholar
  68. 68.
    Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia. 1991;29:48–64.PubMedGoogle Scholar
  69. 69.
    Mathur SN, Chu SK, McCormick Z, Chang-Chien G, Marciniak C. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. PM&R. 2014;6(6):506–13.Google Scholar
  70. 70.
    Plassat R, Perrouin Verbe B, Menei P, Menegalli D, Mathe JF, Richard I. Treatment of spasticity with intrathecal baclofen administration: Longterm follow-up, review of 40 patients. Spinal Cord. 2004;42:686–93.PubMedGoogle Scholar
  71. 71.
    Sadiq SA, Wang GC. Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol. 2006;253:563–9.PubMedGoogle Scholar
  72. 72.
    Winter G, Beni-Adani L, Ben-Pazi H. Intrathecal baclofen therapy—practical approach: clinical benefits and complication management. J Child Neurol. 2018;33(11):734–41.PubMedGoogle Scholar
  73. 73.
    Gilmartin R, Bruce D, Storrs BB, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol. 2000;15:71–7.PubMedGoogle Scholar
  74. 74.
    Dan B, Motta F, Vles JS. Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity. Eur J Paediatr Neurol. 2010;14:19–28.PubMedGoogle Scholar
  75. 75.
    Hasnat MJ, Rice JE. Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cochrane Database Syst Rev. 2015;11:CD004552. Scholar
  76. 76.
    Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. Dev Med Child Neurol. 2000;42:634–45.PubMedGoogle Scholar
  77. 77.
    Blackburn TP, editor. GABAB receptor pharmacology: a tribute to Norman Bowery. 1st ed. San Diego: Academic Press; 2010.Google Scholar
  78. 78.
    Woon K, Tsegaye M, Vloeberghs MH. The role of intrathecal baclofen in the management of primary and secondary dystonia in children. Br J Neurosurg. 2007;21:355–8.PubMedGoogle Scholar
  79. 79.
    Medtronic. Synchromed II drug infusion system brief statement. Retrieved July 31, 2019 from:
  80. 80.
    Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009;11:153–61.PubMedGoogle Scholar
  81. 81.
    Pin TW, McCartney L, Lewis J, et al. Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. Dev Med Child Neurol. 2011;53:885–95.PubMedGoogle Scholar
  82. 82.
    Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol. 1996;11(1_suppl):S29–35.PubMedGoogle Scholar
  83. 83.
    Muller H. Treatment of severe spasticity: results of a multi-center trial conducted in Germany involving the intrathecal infusion of baclofen by an implantable drug delivery system. Dev Med Child Neurol. 1992;34:739–45.Google Scholar
  84. 84.
    Saulino M, Ivanhoe CB, McGuire JR, Ridley B, Shilt JS, Boster AL. Best practices for intrathecal baclofen therapy: patient selection. Neuromodulation. 2016;19(6):607–15.PubMedGoogle Scholar
  85. 85.
    Rifici C, Kofler M, Kronenberg M, Kofler A, Bramanti P, Saltuari L. Intrathecal baclofen application in patients with supraspinal spasticity secondary to severe traumatic brain injury. Funct Neurol. 1994;9(1):29–34.PubMedGoogle Scholar
  86. 86.
    Schuele SU, Kellinghaus C, Shook SJ, Boulis N, Bethoux FA, Loddenkemper T. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology. 2005;64:1086–7.PubMedGoogle Scholar
  87. 87.
    Zak R, Solomon G, Petito F, Labar D. Baclofen-induced generalized non-convulsive status epilepticus. Ann Neurol. 1994;36:113–4.PubMedGoogle Scholar
  88. 88.
    Buonaguro V, Scelsa B, Curci D, Monforte S, Iuorno T, Motta F. Epilepsy and intrathecal baclofen therapy in children with cerebral palsy. Pediatr Neurol. 2005;33:110–3.PubMedGoogle Scholar
  89. 89.
    Kofler M, Kronenberg MF, Rifici C, Saltuari L, Bauer G. Epileptic seizures associated with intrathecal baclofen application. Neurology. 1994;44:25–7.PubMedGoogle Scholar
  90. 90.
    Burn SC, Zeller R, Drake JM. Do baclofen pumps influence the development of scoliosis in children? J Neurosurg Pediatr. 2010;5:195–9.PubMedGoogle Scholar
  91. 91.
    Krach LE, Walker K, Rapp L. The effect of intrathecal baclofen treatment on the development of scoliosis in individuals with cerebral palsy: a retrospective case-matched review. Dev Med Child Neurol. 2005;47:14.Google Scholar
  92. 92.
    Senaran H, Shah SA, Presedo A, et al. The risk of progression of scoliosis in cerebral palsy patients after intrathecal baclofen therapy. Spine (Phila Pa 1976). 2007;32:2348–54.Google Scholar
  93. 93.
    Fulkerson DH, Boaz JC, Luerssen TG. Interaction of ventriculoperitoneal shunt and baclofen pump. Childs Nerv Syst. 2007;23:733–8.PubMedGoogle Scholar
  94. 94.
    Turner MS. Assessing syndromes of catheter malfunction with SynchroMed infusion systems: the value of spiral computed tomography with contrast injection. PM R. 2010;2:757–66.PubMedGoogle Scholar
  95. 95.
    Pucks-Faes E, Matzak H, Hitzenberger G, Genelin E, Halbmayer L, Fava E, Saltuari L. Intrathecal baclofen trial before device implantation: 12-year experience with continuous administration. Arch Phys Med Rehabil. 2019;100(5):837–43.PubMedGoogle Scholar
  96. 96.
    Medtronic. MRI and diagnostic testing compatibility. Retrieved July 31, 2019 from:
  97. 97.
    Kopell BH, Sala D, Doyle WK, Feldman DS, Wisoff JH, Weiner HL. Subfascial implantation of intrathecal baclofen pumps in children: technical note. Neurosurgery. 2001;49:753–7.PubMedGoogle Scholar
  98. 98.
    Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg Pediatr. 2014;13:301–6.PubMedGoogle Scholar
  99. 99.
    Aljuboori Z, Archer J, Huff W, Moreno A, Jea A. Placement of baclofen pump catheter through a C1–2 puncture: technical note. J Neurosurg Pediatr. 2018;21(4):389–94.PubMedGoogle Scholar
  100. 100.
    Albright AL, Ferson SS. Intrathecal baclofen therapy in children. Neurosurg Focus. 2006;21(2):e3.PubMedGoogle Scholar
  101. 101.
    McCall T, MacDonald J. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery. 2006;59(3):634–40.PubMedGoogle Scholar
  102. 102.
    Berweck S, Lutjen S, Voss W, et al. Use of intrathecal baclofen in children and adolescents: interdisciplinary consensus table 2013. Neuropediatrics. 2014;45:294–308.PubMedGoogle Scholar
  103. 103.
    Ross JC, Cook AM, Stewart GL, Fahy BG. Acute intrathecal baclofen withdrawal: a brief review of treatment options. Neurocrit Care. 2011;14:103–8.PubMedGoogle Scholar
  104. 104.
    Watve SV, Sivan M, Raza WA, Jamil FF. Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord. 2012;50:107–11.PubMedGoogle Scholar
  105. 105.
    Stewart K, Hutana G, Kentish M. Intrathecal baclofen therapy in paediatrics: a study protocol for an Australian multicentre, 10-year prospective audit. BMJ Open. 2017;7(6):e015863.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Bayhan IA, Sees JP, Nishnianidze T, Rogers KJ, Miller F. Infection as a complication of intrathecal baclofen treatment in children with cerebral palsy. J Pediatr Orthop. 2016;36(3):305–9.PubMedGoogle Scholar
  107. 107.
    Malheiro L, Gomes A, Barbosa P, Santos L, Sarmento A. Infectious complications of intrathecal drug administration systems for spasticity and chronic pain: 145 patients from a tertiary care center. Neuromodulation. 2015;18(5):421–7.PubMedGoogle Scholar
  108. 108.
    Motta F, Antonello C. Comparison between an Ascenda and a silicone catheter in intrathecal baclofen therapy in pediatric patients: analysis of complications. J Neurosurg Pediatr PED. 2016;18(4):493–8.Google Scholar
  109. 109.
    Buxton K, Morgan A, Rogers J. Nurse practitioner lead pediatric baclofen pump program: impact on safety and quality of care. J Neurosci Nurs. 2017;49(5):324–9.PubMedGoogle Scholar
  110. 110.
    Fernandes P, Dolan L, Weinstein SL. Intrathecal baclofen withdrawal syndrome following posterior spinal fusion for neuromuscular scoliosis: a case report. Iowa Orthop J. 2008;28:77–80.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Mckinnon W, Lee MC, Kanev P. Mortality from intrathecal baclofen withdrawal following posterior spinal fusion. JBJS Case Connect. 2012;2(3):e32.PubMedGoogle Scholar
  112. 112.
    Caird M, Palanca A, Garton H, Hensinger R, Ayyangar R, Drongowski A, Farley F. Outcomes of posterior spinal fusion and instrumentation in patients with continuous intrathecal baclofen infusion pumps. Spine. 2007;33(4):E94–9.Google Scholar
  113. 113.
    Gooch JL, Oberg WA, Grams B, et al. Complications of intrathecal baclofen pumps in children. Pediatr Neurosurg. 2003;39:1–6.PubMedGoogle Scholar
  114. 114.
    Boster AL, Bennett SE, Bilsky GS, et al. Best practices for intrathecal baclofen therapy: screening test. Neuromodulation. 2016;19:623–31.PubMedGoogle Scholar
  115. 115.
    Newberg NL, Gooch JL, Walker ML. Intraoperative monitoring in selective dorsal rhizotomy. Pediatr Neurosurg. 1991;17(3):124–7.PubMedGoogle Scholar
  116. 116.
    Kan P, Gooch J, Amini A, et al. Surgical treatment of spasticity in children: comparison of selective dorsal rhizotomy and intrathecal baclofen pump implantation. Childs Nerv Syst. 2008;24(2):239–43.PubMedGoogle Scholar
  117. 117.
    Oki A, Oberg W, Siebert B, Plante D, Walker ML, Gooch JL. Selective dorsal rhizotomy in children with spastic hemiparesis. J Neurosurg Pediatr. 2010;6(4):353–8.PubMedGoogle Scholar
  118. 118.
    Reynolds MR, Ray WZ, Strom RG, Blackburn SL, Lee A, Park TS. Clinical outcomes after selective dorsal rhizotomy in an adult population. World Neurosurg. 2011;75(1):138–44.PubMedGoogle Scholar
  119. 119.
    Tilton AH. Therapeutic interventions for tone abnormalities in cerebral palsy. NeuroRx. 2006;3(2):217–24.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Tilton A. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2009;16(2):82–9.PubMedGoogle Scholar
  121. 121.
    Park TS, Gaffney PE, Kaufman BA, Molleston MC. Selective lumbosacral dorsal rhizotomy immediately caudal to the conus medullaris for cerebral palsy spasticity. Neurosurgery. 1993;33(5):929–33.PubMedGoogle Scholar
  122. 122.
    Steinbok P, Tidemann AJ, Miller S, Mortenson P, Bowen-Roberts T. Electrophysiologically guided versus non-electrophysiologically guided selective dorsal rhizotomy for spastic cerebral palsy: a comparison of outcomes. Child’s Nerv Syst: ChNS. 2009;25(9):1091–6.Google Scholar
  123. 123.
    Steinbok P, Reiner AM, Beauchamp R, Armstrong RW, Cochrane DD, Kestle J. A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Dev Med Child Neurol. 1997;39(3):178–84.PubMedGoogle Scholar
  124. 124.
    McLaughlin JF, Bjornson KF, Astley SJ, et al. Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol. 1998;40(4):220–32.PubMedGoogle Scholar
  125. 125.
    McLaughlin J, Bjornson K, Temkin N, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol. 2002;44(1):17–25.PubMedGoogle Scholar
  126. 126.
    Wright FV, Sheil EM, Drake JM, Wedge JH, Naumann S. Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled tria. Dev Med Child Neurol. 1998;40(4):239–47.PubMedGoogle Scholar
  127. 127.
    Nordmark E, Josenby AL, Lagergren J, Andersson G, Stromblad LG, Westbom L. Long-term outcomes five years after selective dorsal rhizotomy. BMC Pediatr. 2008;8:54.PubMedPubMedCentralGoogle Scholar
  128. 128.
    Gigante P, McDowell MM, Bruce SS, et al. Reduction in upper-extremity tone after lumbar selective dorsal rhizotomy in children with spastic cerebral palsy. J Neurosurg Pediatr. 2013;12:588–94.PubMedGoogle Scholar
  129. 129.
    Engsberg JR, Ross SA, Park TS. Changes in ankle spasticity and strength following selective dorsal rhizotomy and physical therapy for spastic cerebral palsy. J Neurosurg. 1999;91(5):727–32.PubMedGoogle Scholar
  130. 130.
    Langerak NG, Lamberts RP, Fieggen AG, et al. A prospective gait analysis study in patients with diplegic cerebral palsy 20 years after selective dorsal rhizotomy. J Neurosurg Pediatr. 2008;1(3):180–6.PubMedGoogle Scholar
  131. 131.
    Steinbok P. Outcomes after selective dorsal rhizotomy for spastic cerebral palsy. Childs Nerv Syst. 2001;17(1–2):1–18.PubMedGoogle Scholar
  132. 132.
    Mittal S, Farmer JP, Al-Atassi B, et al. Impact of selective posterior rhizotomy on fine motor skills. Long-term results using a validated evaluative measure. Pediatr Neurosurg. 2002;36(3):133–41.PubMedGoogle Scholar
  133. 133.
    Ghotbi N, Ansari NN, Naghdi S, Hasson S, Jamshidpour B, Amiri S. Inter-rater reliability of the modified modified Ashworth scale in assessing lower limb muscle spasticity. Brain Inj: [BI]. 2009;23(10):815–9.Google Scholar
  134. 134.
    Loewen P, Steinbok P, Holsti L, MacKay M. Upper extremity performance and self-care skill changes in children with spastic cerebral palsy following selective posterior rhizotomy. Pediatr Neurosurg. 1998;29(4):191–8.PubMedGoogle Scholar
  135. 135.
    Ojemann JG, McKinstry RC, Mukherjee P, Park TS, Burton H. Hand somatosensory cortex activity following selective dorsal rhizotomy: report of three cases with fMRI. Childs Nerv Syst. 2005;21(2):115–21.PubMedGoogle Scholar
  136. 136.
    Steinbok P, Schrag C. Complications after selective posterior rhizotomy for spasticity in children with cerebral palsy. Pediatr Neurosurg. 1998;28(6):300–13.PubMedGoogle Scholar
  137. 137.
    Dudley RW, Parolin M, Gagnon B, et al. Long-term functional benefits of selective dorsal rhizotomy for spastic cerebral palsy. J Neurosurg Pediatr. 2013;12(2):142–50.PubMedGoogle Scholar
  138. 138.
    O’Brien DF, Park TS, Puglisi JA, Collins DR, Leuthardt EC. Effect of selective dorsal rhizotomy on need for orthopedic surgery for spastic quadriplegic cerebral palsy: long-term outcome analysis in relation to age. J Neurosurg. 2004;101(1 Suppl):59–63.PubMedGoogle Scholar
  139. 139.
    Watt JM, Robertson CM, Grace MG. Early prognosis for ambulation of neonatal intensive care survivors with cerebral palsy. Dev Med Child Neurol. 1989;31(6):766–73.PubMedGoogle Scholar
  140. 140.
    Park TS, Edwards C, Liu JL, Walter DM, Dobbs MD. Beneficial effects of childhood selective dorsal rhizotomy in adulthood. Cureus. 2017;9(3):e1077.PubMedPubMedCentralGoogle Scholar
  141. 141.
    Gooch JL, Walker ML. Spinal stenosis after total lumbar laminectomy for selective dorsal rhizotomy. Pediatr Neurosurg. 1996;25(1):28–30.PubMedGoogle Scholar
  142. 142.
    Ravindra VM, Christensen MT, Onwuzulike K, Smith JT, Halvorson K, Brockmeyer DL, Walker ML, Bollo RJ. Risk factors for progressive neuromuscular scoliosis requiring posterior spinal fusion after selective dorsal rhizotomy. J Neurosurg Pediatr. 2017;20(5):456–63.PubMedGoogle Scholar
  143. 143.
    Abdel Ghany WA, Nada M, Mahran MA, Aboud A, Mahran MG, Nasef MA, Gaber M, Sabry T, Ibrahim MH, Taha MH. Combined anterior and posterior lumbar rhizotomy for treatment of mixed dystonia and spasticity in children with cerebral palsy. Neurosurgery. 2016;79(3):336–44.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Heakyung Kim
    • 1
    Email author
  • Eduardo Del Rosario
    • 2
  • Richard Anderson
    • 3
  • Nicole Bainton
    • 2
  • Jared Levin
    • 1
  • Angeline Bowman
    • 4
  1. 1.Pediatric Physical Medicine and RehabilitationColumbia University Irving Medical Center/New York Presbyterian HospitalNew YorkUSA
  2. 2.Division of Pediatric Orthopedic Center for Children, NYU Langone Orthopedic HospitalNew YorkUSA
  3. 3.Division of Pediatric NeurosurgeryColumbia University Irving Medical CenterNew YorkUSA
  4. 4.Department of Physical Medicine and RehabilitationPediatric Rehabilitation Medicine, Michigan MedicineAnn ArborUSA

Personalised recommendations